HRP20200906T1 - Il-18 vezujuće molekule - Google Patents
Il-18 vezujuće molekule Download PDFInfo
- Publication number
- HRP20200906T1 HRP20200906T1 HRP20200906TT HRP20200906T HRP20200906T1 HR P20200906 T1 HRP20200906 T1 HR P20200906T1 HR P20200906T T HRP20200906T T HR P20200906TT HR P20200906 T HRP20200906 T HR P20200906T HR P20200906 T1 HRP20200906 T1 HR P20200906T1
- Authority
- HR
- Croatia
- Prior art keywords
- fragment
- seq
- isolated antibody
- sequence
- isolated
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 2
- 208000035366 Familial hemophagocytic lymphohistiocytosis Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 2
- 238000010367 cloning Methods 0.000 claims 2
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims 2
- 102000044166 interleukin-18 binding protein Human genes 0.000 claims 2
- 108010070145 interleukin-18 binding protein Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 206010021460 Immunodeficiency syndromes Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
1. Izolirano potpuno ljudsko ili kimerno protutijelo ili njegov ulomak koji specifično veže IL-18, ali ne veže IL-18/IL-18 vezujući kompleks proteina, naznačeno time, što izolirano protutijelo ili njegov ulomak sadrži varijabilnu domenu teškog lanca koja sadrži SEQ ID NO: 14 i varijabilnu domenu lakog lanca koja sadrži SEQ ID NO: 16.
2. Izolirano protutijelo ili njegov ulomak prema patentnom zahtjevu 1, naznačeno time, što izolirano protutijelo ili njegov ulomak je izolirano potpuno ljudsko protutijelo ili njegov ulomak.
3. Izolirano protutijelo ili njegov ulomak prema patentnom zahtjevu 1, naznačeno time, što izolirano protutijelo ili njegov ulomak je ulomak protutijela odabran iz skupine koja se sastoji od Fab, Fab', F(ab')2, i scFv.
4. Izolirano protutijelo ili njegov ulomak prema patentnom zahtjevu 1, naznačeno time, što izolirano protutijelo ili njegov ulomak sadrži teški lanac koji sadrži SEQ ID NO: 43 i laki lanac koji sadrži SEQ ID NO: 45.
5. Izolirani polinukleotid, naznačen time, što kodira izolirano protutijelo ili njegov ulomak prema bilo kojem od patentnih zahtjeva 1 do 4.
6. Izolirani polinukleotid prema patentnom zahtjevu 5, naznačen time, što obuhvaća:
i. SEQ ID NO: 15 ili sekvencu koja je najmanje 90% njoj identična; ili
ii. SEQ ID NO: 17 ili sekvencu koja je najmanje 90% njoj identična; ili
iii. SEQ ID NO: 15 ili sekvencu koja je najmanje 90% njoj identična, i SEQ ID NO: 17 ili sekvencu koja je najmanje 90% njoj identična; ili
iv. SEQ ID NO: 44 ili sekvencu koja je najmanje 90% njoj identična; ili
v. SEQ ID NO: 46 ili sekvencu koja je najmanje 90% njoj identična; ili
vi. SEQ ID NO: 44 ili sekvencu koja je najmanje 90% njoj identična, i SEQ ID NO: 46 ili sekvencu koja je najmanje 90% njoj identična.
7. Vektor kloniranja ili ekspresije, naznačen time, što sadrži jedan ili više polinukleotida prema bilo kojem od patentnih zahtjeva 5 ili 6.
8. Stanica domaćina, naznačena time, što sadrži jedan ili više vektora za kloniranje ili za ekspresiju, prema patentnom zahtjevu 7.
9. Stabilno transformirana ili transficirana stanica domaćina, naznačena time, što sadrži jedan ili više polinukleotida prema bilo kojem od patentnih zahtjeva 5 ili 6.
10. Postupak za proizvodnju izoliranog potpuno ljudskog ili kimernog protutijela ili njegovog ulomka koji specifično veže IL-18, ali ne veže IL-18/IL-18 vezujući kompleks proteina, naznačen time, što postupak obuhvaća kultiviranje stanice domaćina prema zahtjevu 8, pod uvjetima koji su pogodni za proizvodnju izoliranog protutijela ili njegovog ulomka.
11. Farmaceutski pripravak, naznačen time, što sadrži izolirano protutijelo ili njegov ulomak prema bilo kojem od patentnih zahtjeva 1 do 4 i farmaceutski nosač, pri čemu farmaceutski pripravak po izboru sadrži drugi terapeutski spoj.
12. Farmaceutski pripravak prema patentnom zahtjevu 11, naznačen time, što se nalazi u obliku koji se primjenjuje intravenski, za inhaliranje ili potkožno.
13. Izolirano protutijelo ili njegov ulomak prema bilo kojem od patentnih zahtjeva 1 do 4 ili farmaceutski pripravak prema zahtjevima 11 ili 12, naznačeni time, što se upotrebljavaju u terapiji.
14. Izolirano protutijelo ili njegov ulomak prema bilo kojem od patentnih zahtjeva 1 do 4 ili farmaceutski pripravak prema zahtjevima 11 ili 12, naznačeni time, što su za uporabu u liječenju i/ili sprečavanju sarkoidoze, naročito plućne sarkoidoze, hemofagocitne limfohistiocitoze (HLH), obiteljske hemofagocitne limfohistiocitoze (FHL) i drugih sindroma imunodeficijencije, arteritisa divovskih stanica (GCA), kronične opstruktivne plućne bolesti (KOPB), Stillove bolesti odrasle dobi (AOSD), sistemskog juvenilnog idiopatskog artritisa (SJIA), teške astme, uveitisa, geografske atrofije, dijabetesa tipa 1, dijabetesa tipa 2 ili ateroskleroze te bilo koje njihove kombinacije kod pacijenta sisavca.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261697981P | 2012-09-07 | 2012-09-07 | |
PCT/IB2013/058317 WO2014037899A2 (en) | 2012-09-07 | 2013-09-05 | Il-18 binding molecules |
EP13792452.8A EP2892923B1 (en) | 2012-09-07 | 2013-09-05 | Il-18 binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200906T1 true HRP20200906T1 (hr) | 2020-09-04 |
Family
ID=49596347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200906TT HRP20200906T1 (hr) | 2012-09-07 | 2020-06-05 | Il-18 vezujuće molekule |
Country Status (41)
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
HUE055608T2 (hu) * | 2013-09-05 | 2021-12-28 | Ab2 Bio Sa | IL-18-kötõ fehérje (IL-18BP) gyulladásos betegségekben |
WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
AU2016227644B2 (en) * | 2015-03-05 | 2022-06-16 | Ab2 Bio Sa | IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases |
WO2017076805A1 (en) * | 2015-11-02 | 2017-05-11 | Glaxosmithkline Intellectual Property Development Limited | Use of an inhibitor of il18 for treatment of acute kidney injury |
US10894830B2 (en) * | 2015-11-03 | 2021-01-19 | Janssen Biotech, Inc. | Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses |
CN108218978B (zh) * | 2016-12-13 | 2020-05-12 | 沈阳何氏眼产业集团有限公司 | 一种重组白细胞介素18及其制备方法与应用 |
CN110382002A (zh) | 2017-03-09 | 2019-10-25 | Mab发现股份有限公司 | 特异性结合人il-1r7的抗体 |
UY37758A (es) * | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
WO2019051015A1 (en) * | 2017-09-06 | 2019-03-14 | Yale University | VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE |
WO2019213686A1 (en) * | 2018-05-10 | 2019-11-14 | The Council Of The Queensland Institute Of Medical Research | Therapeutic compositions and uses therefor |
WO2020116423A1 (ja) | 2018-12-03 | 2020-06-11 | 株式会社mAbProtein | 活性型インターロイキン-18タンパク質のネオエピトープを認識する抗体、及びその応用 |
CN109870570A (zh) * | 2018-12-29 | 2019-06-11 | 广东云天抗体生物科技有限公司 | 一种检测猴il-18的酶联免疫试剂盒 |
TW202233675A (zh) | 2020-10-29 | 2022-09-01 | 瑞士商諾華公司 | Il-18拮抗劑用於治療和/或預防異位性皮炎或相關病症之用途 |
WO2022221264A1 (en) * | 2021-04-12 | 2022-10-20 | Ethos Biosciences, Inc. | Methods and compositions for analysis of acute kidney injury |
JP2023535884A (ja) | 2021-06-22 | 2023-08-22 | ノバルティス アーゲー | 化膿性汗腺炎の処置における使用のための二特異性抗体 |
WO2023286694A1 (ja) | 2021-07-13 | 2023-01-19 | 国立大学法人東海国立大学機構 | 炎症性腸疾患を治療するための医薬組成物 |
CN117177999A (zh) * | 2022-01-14 | 2023-12-05 | 和径医药科技(上海)有限公司 | 一种靶向IL-18Rβ的抗体及其应用 |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
TW202400658A (zh) * | 2022-04-26 | 2024-01-01 | 瑞士商諾華公司 | 靶向il—13和il—18的多特異性抗體 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH03230220A (ja) | 1990-02-05 | 1991-10-14 | Seiko Epson Corp | ソート処理方法 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
DK0701571T3 (da) | 1993-06-03 | 1997-09-15 | Therapeutic Antibodies Inc | Antistoffragmenter til terapi |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
TW464656B (en) | 1994-11-15 | 2001-11-21 | Hayashibara Biochem Lab | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
JP2009047705A (ja) | 1996-07-31 | 2009-03-05 | Hayashibara Biochem Lab Inc | 生物学的試料の検出方法 |
JP2007121310A (ja) | 1996-07-31 | 2007-05-17 | Hayashibara Biochem Lab Inc | 自己免疫疾患診断剤 |
US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
IL137178A0 (en) | 1998-01-23 | 2001-07-24 | Immunex Corp | Il-18 receptors |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6432678B1 (en) | 1999-06-21 | 2002-08-13 | Smithkline Beecham Corporation | Macaca cynomolgus IL 18 |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
JP3230220B2 (ja) | 1999-10-07 | 2001-11-19 | 独立行政法人 農業技術研究機構 | ブタ由来インターロイキン−18に対するモノクローナル抗体 |
DE60041432D1 (de) | 1999-11-16 | 2009-03-12 | Hayashibara Biochem Lab | Antikörper spezifisch für den Interleukin-18 Vorläufer |
CN102206277A (zh) | 2000-02-10 | 2011-10-05 | 雅培制药有限公司 | 结合人白介素-18的抗体及制备和使用方法 |
TR200502061T2 (tr) * | 2000-02-21 | 2005-08-22 | Research Systems Ars Holding N. V. Applied | IL-18 inhibitörlerinin kullanımı. |
EP1278540B1 (en) | 2000-05-05 | 2008-05-14 | Laboratoires Serono SA | Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
EP2339013B1 (en) | 2000-06-28 | 2014-07-02 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002032374A2 (en) | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
DK1355668T3 (da) | 2001-01-29 | 2008-05-05 | Serono Lab | Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
US20040023336A1 (en) | 2001-10-26 | 2004-02-05 | Heavner George A. | Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses |
SI1487541T1 (sl) | 2002-03-22 | 2009-02-28 | Serono Lab | Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja |
FR2838444B1 (fr) | 2002-04-10 | 2016-01-01 | Neovacs | Nouveaux peptides et leur application en therapeutique |
EP1621616A4 (en) * | 2003-04-30 | 2007-07-04 | Japan Science & Tech Agency | ANTIHUMAN INTERLEUKIN-18 HUMAN ANTIBODY, FRAGMENT THEREOF AND METHOD OF USING SAME |
WO2004101617A1 (en) | 2003-05-13 | 2004-11-25 | Applied Research Systems Ars Holding N.V. | Active variants of the il-18 binding protein and medical uses thereof |
DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
ATE414106T1 (de) | 2003-06-30 | 2008-11-15 | Domantis Ltd | Pegylierte single-domain-antikörper (dab) |
JP2005052021A (ja) | 2003-08-07 | 2005-03-03 | Yokohama City | インターロイキン−18変異体タンパク質 |
US20050075702A1 (en) | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
WO2005075648A1 (en) | 2004-01-28 | 2005-08-18 | Gifu University | Interleukin-18 mutant proteins |
JP2007523099A (ja) | 2004-02-20 | 2007-08-16 | ノボ ノルディスク アクティーゼルスカブ | 組み合わせ療法 |
US7557084B2 (en) | 2004-03-31 | 2009-07-07 | Regeneron Pharmaceuticals, Inc. | IL-18 specific polypeptides and therapeutic uses thereof |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Th1型アレルギー疾患治療用組成物 |
CA2613204A1 (en) | 2005-06-29 | 2007-01-11 | Rules-Based Medicine, Inc. | Methods and kits for the diagnosis of acute coronary syndrome |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
EP2500352A1 (en) | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
ES2735531T3 (es) | 2005-08-23 | 2019-12-19 | Univ Pennsylvania | ARN que contiene nucleósidos modificados y métodos de uso del mismo |
JP4728785B2 (ja) | 2005-11-30 | 2011-07-20 | 独立行政法人科学技術振興機構 | Il−18の生物活性を有する新規ポリペプチドの生産方法、および当該ポリペプチドの産生を阻害する物質のスクリーニング方法 |
EA017303B1 (ru) | 2006-05-25 | 2012-11-30 | Глаксо Груп Лимитед | Модифицированные гуманизированные антитела против интерлейкина-18 и их применение |
WO2009025846A2 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
MX2010008364A (es) | 2008-01-30 | 2010-08-23 | Abbott Lab | Composiciones y metodos para cristalizar fragmentos de anticuerpo. |
CN102112494A (zh) | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
JP5674654B2 (ja) | 2008-07-08 | 2015-02-25 | アッヴィ・インコーポレイテッド | プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用 |
EP2326315A1 (en) | 2008-08-18 | 2011-06-01 | Glaxo Group Limited | Treatment of an autoimmune disease using il-18 antagonists |
WO2010040736A2 (en) | 2008-10-07 | 2010-04-15 | Ablynx Nv | Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling |
AU2009307728B2 (en) | 2008-10-20 | 2014-12-11 | Abbvie Inc. | Antibodies that bind to IL-18 and methods of purifying the same |
AU2009307737B2 (en) | 2008-10-20 | 2015-07-23 | Abbvie Inc. | Viral inactivation during purification of antibodies |
JP2013514556A (ja) | 2008-12-23 | 2013-04-25 | エムティエヌ・モバイル・マネー・エスエイ・(プロプライエタリー)・リミテッド | 安全に取引を処理するための方法及びシステム |
AU2010242840B2 (en) | 2009-05-01 | 2014-04-17 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
WO2011098424A2 (en) | 2010-02-09 | 2011-08-18 | Glaxo Group Limited | Treatment of a metabolic disorder |
US9255144B2 (en) * | 2010-12-20 | 2016-02-09 | Medimmune Limited | Anti-IL-18 antibodies and their uses |
JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
UY37758A (es) * | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
-
2012
- 2012-09-07 JO JOP/2020/0308A patent/JOP20200308A1/ar unknown
-
2013
- 2013-09-04 US US14/017,561 patent/US9376489B2/en active Active
- 2013-09-05 SG SG10201706623WA patent/SG10201706623WA/en unknown
- 2013-09-05 KR KR1020157008513A patent/KR102207672B1/ko active IP Right Grant
- 2013-09-05 AU AU2013311234A patent/AU2013311234A1/en not_active Abandoned
- 2013-09-05 MY MYPI2015700574A patent/MY174691A/en unknown
- 2013-09-05 KR KR1020217001854A patent/KR102330653B1/ko active IP Right Grant
- 2013-09-05 SI SI201331738T patent/SI2892923T1/sl unknown
- 2013-09-05 LT LTEP13792452.8T patent/LT2892923T/lt unknown
- 2013-09-05 CN CN201380046530.3A patent/CN104640879B/zh active Active
- 2013-09-05 CN CN201811364662.1A patent/CN109517065B/zh active Active
- 2013-09-05 EA EA201992614A patent/EA201992614A3/ru unknown
- 2013-09-05 PE PE2015000304A patent/PE20150649A1/es active IP Right Grant
- 2013-09-05 MA MA37892A patent/MA37892A1/fr unknown
- 2013-09-05 PT PT137924528T patent/PT2892923T/pt unknown
- 2013-09-05 EA EA201590523A patent/EA034610B1/ru not_active IP Right Cessation
- 2013-09-05 EP EP13792452.8A patent/EP2892923B1/en active Active
- 2013-09-05 CA CA2883821A patent/CA2883821C/en active Active
- 2013-09-05 AP AP2015008266A patent/AP2015008266A0/xx unknown
- 2013-09-05 SG SG11201501559VA patent/SG11201501559VA/en unknown
- 2013-09-05 JP JP2015530535A patent/JP6404817B2/ja active Active
- 2013-09-05 HU HUE13792452A patent/HUE050464T2/hu unknown
- 2013-09-05 RS RS20200663A patent/RS60394B1/sr unknown
- 2013-09-05 MX MX2015002986A patent/MX2015002986A/es active IP Right Grant
- 2013-09-05 WO PCT/IB2013/058317 patent/WO2014037899A2/en active Application Filing
- 2013-09-05 BR BR112015004783-1A patent/BR112015004783B1/pt active IP Right Grant
- 2013-09-05 EP EP20157418.3A patent/EP3725805A1/en active Pending
- 2013-09-05 JO JOP/2013/0269A patent/JO3764B1/ar active
- 2013-09-05 ES ES13792452T patent/ES2804704T3/es active Active
- 2013-09-05 BR BR122019028128-9A patent/BR122019028128B1/pt active IP Right Grant
- 2013-09-05 PL PL13792452T patent/PL2892923T3/pl unknown
- 2013-09-05 DK DK13792452.8T patent/DK2892923T3/da active
- 2013-09-06 TW TW102132287A patent/TWI613217B/zh active
- 2013-09-06 UY UY0001035016A patent/UY35016A/es not_active Application Discontinuation
- 2013-09-06 AR ARP130103173A patent/AR092465A1/es unknown
- 2013-09-06 TW TW106136512A patent/TWI655208B/zh active
-
2015
- 2015-02-09 IL IL237161A patent/IL237161B/en active IP Right Grant
- 2015-02-10 ZA ZA2015/00954A patent/ZA201500954B/en unknown
- 2015-02-19 TN TNP2015000057A patent/TN2015000057A1/fr unknown
- 2015-03-04 CL CL2015000532A patent/CL2015000532A1/es unknown
- 2015-03-04 PH PH12015500466A patent/PH12015500466B1/en unknown
- 2015-03-06 CU CUP2015000022A patent/CU24249B1/es unknown
- 2015-03-06 CR CR20150121A patent/CR20150121A/es unknown
- 2015-03-06 MX MX2020007022A patent/MX2020007022A/es unknown
- 2015-03-06 GT GT201500054A patent/GT201500054A/es unknown
- 2015-03-06 CO CO15052159A patent/CO7400884A2/es unknown
- 2015-04-06 EC ECIEPI201513209A patent/ECSP15013209A/es unknown
- 2015-10-06 HK HK15109750.4A patent/HK1209136A1/xx unknown
-
2016
- 2016-03-18 AU AU2016201741A patent/AU2016201741B2/en active Active
- 2016-05-25 US US15/164,508 patent/US10081677B2/en active Active
-
2017
- 2017-12-06 AU AU2017272201A patent/AU2017272201B2/en active Active
-
2018
- 2018-08-24 US US16/111,659 patent/US11111293B2/en active Active
- 2018-09-12 JP JP2018170754A patent/JP2019037230A/ja active Pending
-
2019
- 2019-07-29 IL IL268336A patent/IL268336B/en unknown
- 2019-12-27 JP JP2019238049A patent/JP6944509B2/ja active Active
-
2020
- 2020-03-03 AU AU2020201556A patent/AU2020201556B2/en active Active
- 2020-06-05 HR HRP20200906TT patent/HRP20200906T1/hr unknown
- 2020-06-24 CY CY20201100582T patent/CY1123071T1/el unknown
-
2021
- 2021-07-27 US US17/386,429 patent/US20220098296A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200906T1 (hr) | Il-18 vezujuće molekule | |
HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
HRP20191775T1 (hr) | Multispecifične konstrukcije antitijela | |
HRP20210096T1 (hr) | Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe | |
HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba | |
HRP20180147T1 (hr) | Cea protutijela | |
JP2010535012A5 (hr) | ||
MX2018013548A (es) | Proteinas de union biespecificas y usos de las mismas. | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
MX2017009052A (es) | Anticuerpos de unión a april modificados. | |
MX341921B (es) | Proteinas de union a antigeno. | |
JP2012034692A5 (hr) | ||
WO2015108998A3 (en) | Cartilage targeting agents and their use | |
IN2014CN03936A (hr) | ||
TN2012000145A1 (en) | Bispecific binding molecules for anti-angiogenesis therapy | |
MX353813B (es) | Moleculas de union a vegf. | |
JP2016500673A5 (hr) | ||
NZ721184A (en) | Therapeutic peptides | |
NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
HRP20192313T1 (hr) | Novo anti-netrin-1 protutijelo | |
EA201200549A1 (ru) | Dll4-связывающие молекулы |